These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 27435393)

  • 1. Inhibition of the EGFR/STAT3/CEBPD Axis Reverses Cisplatin Cross-resistance with Paclitaxel in the Urothelial Carcinoma of the Urinary Bladder.
    Wang WJ; Li CF; Chu YY; Wang YH; Hour TC; Yen CJ; Chang WC; Wang JM
    Clin Cancer Res; 2017 Jan; 23(2):503-513. PubMed ID: 27435393
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MiR-193b Mediates CEBPD-Induced Cisplatin Sensitization Through Targeting ETS1 and Cyclin D1 in Human Urothelial Carcinoma Cells.
    Lin SR; Yeh HC; Wang WJ; Ke HL; Lin HH; Hsu WC; Chao SY; Hour TC; Wu WJ; Pu YS; Huang AM
    J Cell Biochem; 2017 Jun; 118(6):1563-1573. PubMed ID: 27918099
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibiting Importin 4-mediated nuclear import of CEBPD enhances chemosensitivity by repression of PRKDC-driven DNA damage repair in cervical cancer.
    Zhou Y; Liu F; Xu Q; Yang B; Li X; Jiang S; Hu L; Zhang X; Zhu L; Li Q; Zhu X; Shao H; Dai M; Shen Y; Ni B; Wang S; Zhang Z; Teng Y
    Oncogene; 2020 Aug; 39(34):5633-5648. PubMed ID: 32661323
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Overcoming resistance of targeted EGFR monotherapy by inhibition of STAT3 escape pathway in soft tissue sarcoma.
    Wang X; Goldstein D; Crowe PJ; Yang M; Garrett K; Zeps N; Yang JL
    Oncotarget; 2016 Apr; 7(16):21496-509. PubMed ID: 26909593
    [TBL] [Abstract][Full Text] [Related]  

  • 5. VEGF-C inhibition reverses resistance of bladder cancer cells to cisplatin via upregulating maspin.
    Zhu H; Yun F; Shi X; Wang D
    Mol Med Rep; 2015 Aug; 12(2):3163-9. PubMed ID: 25936422
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Down-regulation of NF kappa B activation is an effective therapeutic modality in acquired platinum-resistant bladder cancer.
    Ito Y; Kikuchi E; Tanaka N; Kosaka T; Suzuki E; Mizuno R; Shinojima T; Miyajima A; Umezawa K; Oya M
    BMC Cancer; 2015 Apr; 15():324. PubMed ID: 25926105
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Growth and molecular interactions of the anti-EGFR antibody cetuximab and the DNA cross-linking agent cisplatin in gefitinib-resistant MDA-MB-468 cells: new prospects in the treatment of triple-negative/basal-like breast cancer.
    Oliveras-Ferraros C; Vazquez-Martin A; López-Bonet E; Martín-Castillo B; Del Barco S; Brunet J; Menendez JA
    Int J Oncol; 2008 Dec; 33(6):1165-76. PubMed ID: 19020749
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Transcriptional up-regulation of SOD1 by CEBPD: a potential target for cisplatin resistant human urothelial carcinoma cells.
    Hour TC; Lai YL; Kuan CI; Chou CK; Wang JM; Tu HY; Hu HT; Lin CS; Wu WJ; Pu YS; Sterneck E; Huang AM
    Biochem Pharmacol; 2010 Aug; 80(3):325-34. PubMed ID: 20385105
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Functional Genetic Screen Identifies the Phosphoinositide 3-kinase Pathway as a Determinant of Resistance to Fibroblast Growth Factor Receptor Inhibitors in FGFR Mutant Urothelial Cell Carcinoma.
    Wang L; Šuštić T; Leite de Oliveira R; Lieftink C; Halonen P; van de Ven M; Beijersbergen RL; van den Heuvel MM; Bernards R; van der Heijden MS
    Eur Urol; 2017 Jun; 71(6):858-862. PubMed ID: 28108151
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of the MUC1-C oncoprotein in the acquisition of cisplatin resistance by urothelial carcinoma.
    Shigeta K; Hasegawa M; Kikuchi E; Yasumizu Y; Kosaka T; Mizuno R; Mikami S; Miyajima A; Kufe D; Oya M
    Cancer Sci; 2020 Oct; 111(10):3639-3652. PubMed ID: 32677159
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cross-reacting material 197 reverses the resistance to paclitaxel in paclitaxel-resistant human ovarian cancer.
    Tang XH; Deng S; Li M; Lu MS
    Tumour Biol; 2016 Apr; 37(4):5521-8. PubMed ID: 26572150
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Transcribed ultraconserved region Uc.63+ promotes resistance to cisplatin through regulation of androgen receptor signaling in bladder cancer.
    Sekino Y; Sakamoto N; Ishikawa A; Honma R; Shigematsu Y; Hayashi T; Sentani K; Oue N; Teishima J; Matsubara A; Yasui W
    Oncol Rep; 2019 May; 41(5):3111-3118. PubMed ID: 30864720
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adenovirus-mediated LRIG1 expression enhances the chemosensitivity of bladder cancer cells to cisplatin.
    Yan Z; Jiang J; Li F; Yang W; Xie G; Zhou C; Xia S; Cheng Y
    Oncol Rep; 2015 Apr; 33(4):1791-8. PubMed ID: 25695283
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gefitinib inhibition of drug resistance to doxorubicin by inactivating ABCG2 in thyroid cancer cell lines.
    Lopez JP; Wang-Rodriguez J; Chang C; Chen JS; Pardo FS; Aguilera J; Ongkeko WM
    Arch Otolaryngol Head Neck Surg; 2007 Oct; 133(10):1022-7. PubMed ID: 17938326
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CEBPD amplification and overexpression in urothelial carcinoma: a driver of tumor metastasis indicating adverse prognosis.
    Wang YH; Wu WJ; Wang WJ; Huang HY; Li WM; Yeh BW; Wu TF; Shiue YL; Sheu JJ; Wang JM; Li CF
    Oncotarget; 2015 Oct; 6(31):31069-84. PubMed ID: 26307680
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antagonism between gefitinib and cisplatin in non-small cell lung cancer cells: why randomized trials failed?
    Tsai CM; Chen JT; Stewart DJ; Chiu CH; Lai CL; Hsiao SY; Chen YM; Chang KT
    J Thorac Oncol; 2011 Mar; 6(3):559-68. PubMed ID: 21258258
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Induction of drug-resistant bladder carcinoma cells in vitro: impact on polychemotherapy with cisplatin, methotrexate and vinblastine (CMV).
    Rohde D; Brehmer B; Kapp T; Valdor M; Jakse G
    Urol Res; 1998; 26(4):249-57. PubMed ID: 9759998
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Repression of GRIM19 expression potentiates cisplatin chemoresistance in advanced bladder cancer cells via disrupting ubiquitination-mediated Bcl-xL degradation.
    Ni F; Yan CY; Zhou S; Hui PY; Du YH; Zheng L; Yu J; Hu XJ; Zhang ZG
    Cancer Chemother Pharmacol; 2018 Oct; 82(4):593-605. PubMed ID: 30032449
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gefitinib reverses TRAIL resistance in human bladder cancer cell lines via inhibition of AKT-mediated X-linked inhibitor of apoptosis protein expression.
    Shrader M; Pino MS; Lashinger L; Bar-Eli M; Adam L; Dinney CP; McConkey DJ
    Cancer Res; 2007 Feb; 67(4):1430-5. PubMed ID: 17308080
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CCAAT enhancer binding protein delta activates vesicle associated membrane protein 3 transcription to enhance chemoresistance and extracellular PD-L1 expression in triple-negative breast cancer.
    Zhao Y; Yu Y; Li X; Guo A
    J Exp Clin Cancer Res; 2024 Apr; 43(1):115. PubMed ID: 38627816
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.